clinical trial · NCT06153251
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company·phase1·recruiting·n = 187
Relapsed and/or Refractory Multiple MyelomaBMS-986453FludarabineCyclophosphamide
brief summary
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
started
Jan 23, 2024
primary completion
May 2, 2030
completion
May 2, 2030
last updated
Mar 18, 2026
official title
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol